Lysophospholipid signaling in cardiac myocyte hypertrophy

Journal of Molecular and Cellular Cardiology

Volumn 36, Issue 4, 2004, Pages 465-468

  Wei, Lei ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPID; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

EDITORIAL; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HUMANS; HYPERTROPHY; LYSOPHOSPHOLIPIDS; MODELS, BIOLOGICAL; MYOCARDIUM; MYOCYTES, CARDIAC; RECEPTORS, G-PROTEIN-COUPLED; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 1842815886     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2004.02.006     Document Type: Editorial

References (45)

1. Moolenaar W.H. Lysophosphatidic acid, a multifunctional phospholipid messenger. J Biol Chem. 270:1995;12949-12952.
2. Goetzl E.J., An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J. 12:1998;1589-1598.
3. Karliner J.S. Lysophospholipids and the cardiovascular system. Biochim Biophys Acta. 1582:2002;216-221.
4. Goetzl E.J., Lee H., Azuma T., Stossel T.P., Turck C.W., Karliner J.S. Gelsolin binding and cellular presentation of lysophosphatidic acid. J Biol Chem. 275:2000;14573-14578.
5. Xu Y.J., Ouk Kim S., Liao D.F., Katz S., Pelech S.L. Stimulation of 90- and 70-kDa ribosomal protein S6 kinases by arginine vasopressin and lysophosphatidic acid in rat cardiomyocytes. Biochem Pharmacol. 59:2000;1163-1171.
6. Robert P., Tsui P., Laville M.P., Livi G.P., Sarau H.M., Bril A., Berrebi-Bertrand I. EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol. 33:2001;1589-1606.
7. Sekiguchi K., Yokoyama T., Kurabayashi M., Okajima F., Nagai R. Sphingosylphosphorylcholine induces a hypertrophic growth response through the mitogen-activated protein kinase signaling cascade in rat neonatal cardiac myocytes. Circ Res. 85:1999;1000-1008.
8. Fukushima N., Ishii I., Contos J.J., Weiner J.A., Chun J. Lysophospholipid receptors. Annu Rev Pharmacol Toxicol. 41:2001;507-534.
9. Zhang G., Contos J.J., Weiner J.A., Fukushima N., Chun J. Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate. Gene. 227:1999;89-99.
10. Yang A.H., Ishii I., Chun J. In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice. Biochim Biophys Acta. 1582:2002;197-203.
11. Takuwa Y., Takuwa N., Sugimoto N. The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities. J Biochem (Tokyo). 131:2002;767-771.
12. Hilal-Dandan R., Means C.K., Gustafsson A., Morissette M., Adams J., Brunton L.L., Brown J.H. Lysophosphatidic acid induces hypertrophy of neonatal cardiac myocytes via activation of Gi and Rho. J Mol Cell Cardiol. 36, in this issue:2004.
13. Adams J.W., Sakata Y., Davis M.G., Sah V.P., Wang Y., Liggett S.B., Chien K.R., Brown J.H., Dorn G.W. 2nd. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A. 95:1998;10140-10145.
14. Akhter S.A., Luttrell L.M., Rockman H.A., Iaccarino G., Lefkowitz R.J., Koch W.J. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science. 280:1998;574-577.
15. Wettschureck N., Rutten H., Zywietz A., Gehring D., Wilkie T.M., Chen J., Chien K.R., Offermanns S. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med. 7:2001;1236-1240.
16. Jalili T., Takeishi Y., Walsh R.A. Signal transduction during cardiac hypertrophy: the role of G alpha q, PLC beta I, and PKC. Cardiovasc Res. 44:1999;5-9.
17. Baker A.J., Redfern C.H., Harwood M.D., Simpson P.C., Conklin B.R. Abnormal contraction caused by expression of G(i)-coupled receptor in transgenic model of dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 280:2001;H1653-H1659.
18. Foerster K., Groner F., Matthes J., Koch W.J., Birnbaumer L., Herzig S. Cardioprotection specific for the G protein Gi2 in chronic adrenergic signaling through beta 2-adrenoceptors. Proc Natl Acad Sci U S A. 100:2003;14475-14480.
19. Kilts J.D., Gerhardt M.A., Richardson M.D., Sreeram G., Mackensen G.B., Grocott H.P., White W.D., Davis R.D., Newman M.F., Reves J.G., Schwinn D.A., Kwatra M.M. Beta(2)-adrenergic and several other G protein-coupled receptors in human atrial membranes activate both G(s) and G(i). Circ Res. 87:2000;705-709.
20. Bogoyevitch M.A., Clerk A., Sugden P.H. Activation of the mitogen-activated protein kinase cascade by pertussis toxin-sensitive and -insensitive pathways in cultured ventricular cardiomyocytes. Biochem J. 309:1995;437-443.
21. Hall A. Small GTP-binding proteins and the regulation of the actin cytoskeleton. Annu Rev Cell Biol. 10:1994;31-54.
22. Van Aelst L., D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 11:1997;2295-2322.
23. Hoshijima M., Sah V.P., Wang Y., Chien K.R., Brown J.H. The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. J Biol Chem. 273:1998;7725-7730.
24. Aoki H., Izumo S., Sadoshima J. Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. Circ Res. 82:1998;666-676.
25. Aikawa R., Komuro I., Yamazaki T., Zou Y., Kudoh S., Zhu W., Kadowaki T., Yazaki Y. Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. Circ Res. 84:1999;458-466.
26. Kozasa T., Jiang X., Hart M.J., Sternweis P.M., Singer W.D., Gilman A.G., Bollag G., Sternweis P.C. p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science. 280:1998;2109-2111.
27. Kurose H. Galpha12 and Galpha13 as key regulatory mediator in signal transduction. Life Sci. 74:2003;155-161.
28. Maruyama Y., Nishida M., Sugimoto Y., Tanabe S., Turner J.H., Kozasa T., Wada T., Nagao T., Kurose H. Galpha(12/13) mediates alpha(1)-adrenergic receptor-induced cardiac hypertrophy. Circ Res. 91:2002;961-969.
29. Sah V.P., Minamisawa S., Tam S.P., Wu T.H., Dorn G.W. 2nd, Ross J. Jr, Chien K.R., Brown J.H. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J Clin Invest. 103:1999;1627-1634.
30. Wei L., Taffet G.E., Khoury D.S., Bo J., Li Y., Yatani A., Delaughter M.C., Klevitsky R., Hewett T.E., Robbins J., Michael L.H., Schneider M.D., Entman M.L., Schwartz R.J. Disruption of Rho signaling results in progressive atrioventricular conduction defects while ventricular function remains preserved. FASEB J. 2004;. in press.
31. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., Kitakaze M., Liao J.K. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 108:2001;1429-1437.
32. Patel R., Nagueh S.F., Tsybouleva N., Abdellatif M., Lutucuta S., Kopelen H.A., Quinones M.A., Zoghbi W.A., Entman M.L., Roberts R., Marian A.J. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 104:2001;317-324.
33. Wei L., Wang L., Carson J.A., Agan J.E., Imanaka-Yoshida K., Schwartz R.J. beta1 integrin and organized actin filaments facilitate cardiomyocyte-specific RhoA-dependent activation of the skeletal alpha-actin promoter. FASEB J. 15:2001;785-796.
34. Morissette M.R., Sah V.P., Glembotski C.C., Brown J.H. The Rho effector, PKN, regulates ANF gene transcription in cardiomyocytes through a serum response element. Am J Physiol Heart Circ Physiol. 278:2000;H1769-H1774.
35. Kawamura S., Miyamoto S., Brown J.H. Initiation and transduction of stretch-induced RhoA and Rac1 activation through caveolae: cytoskeletal regulation of ERK translocation. J Biol Chem. 278:2003;3111-3117.
36. Yanazume T., Hasegawa K., Wada H., Morimoto T., Abe M., Kawamura T., Sasayama S. Rho/ROCK pathway contributes to the activation of extracellular signal-regulated kinase/GATA-4 during myocardial cell hypertrophy. J Biol Chem. 277:2002;8618-8625.
37. Charron F., Tsimiklis G., Arcand M., Robitaille L., Liang Q., Molkentin J.D., Meloche S., Nemer M. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev. 15:2001;2702-2719.
38. Kuwahara K., Saito Y., Nakagawa O., Kishimoto I., Harada M., Ogawa E., Miyamoto Y., Hamanaka I., Kajiyama N., Takahashi N., Izumi T., Kawakami R., Tamura N., Ogawa Y., Nakao K. The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiac myocytes - possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lett. 452:1999;314-318.
39. Kobayashi N., Horinaka S., Mita S., Nakano S., Honda T., Yoshida K., Kobayashi T., Matsuoka H. Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res. 55:2002;757-767.
40. Satoh S., Ueda Y., Koyanagi M., Kadokami T., Sugano M., Yoshikawa Y., Makino N. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J Mol Cell Cardiol. 35:2003;59-70.
41. Higashi M., Shimokawa H., Hattori T., Hiroki J., Mukai Y., Morikawa K., Ichiki T., Takahashi S., Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res. 93:2003;767-775.
42. Siess W., Zangl K.J., Essler M., Bauer M., Brandl R., Corrinth C., Bittman R., Tigyi G., Aepfelbacher M. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A. 96:1999;6931-6936.
43. Karliner J.S., Honbo N., Summers K., Gray M.O., Goetzl E.J. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol. 33:2001;1713-1717.
44. Jin Z.Q., Zhou H.Z., Zhu P., Honbo N., Mochly-Rosen D., Messing R.O., Goetzl E.J., Karliner J.S., Gray M.O. Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol. 282:2002;H1970-H1977.
45. Liu Y., Wada R., Yamashita T., Mi Y., Deng C.X., Hobson J.P., Rosenfeldt H.M., Nava V.E., Chae S.S., Lee M.J., Liu C.H., Hla T., Spiegel S., Proia R.L. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 106:2000;951-961.